Goldenwell Biotech, Inc. (GWLL)

Market Cap	103.95M
Revenue (ttm)	62.34K +117,526.4%
Net Income	-75.12K
EPS	-0.00
Shares Out	99.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	913
Open	1.050
Previous Close	n/a
Day's Range	1.050 - 1.050
52-Week Range	0.200 - 10.000
Beta	5.85
RSI	43.86
Earnings Date	May 8, 2026

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2019
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: GWLL

Financial Performance

In 2024, Goldenwell Biotech's revenue was $139, a decrease of -92.43% compared to the previous year's $1,836. Losses were -$131,498, 12.0% more than in 2023.